{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:17:05Z","timestamp":1792588625102,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008478","name":"Instituto Nacional del C\u00e1ncer","doi-asserted-by":"publisher","award":["INC III IS001946"],"award-info":[{"award-number":["INC III IS001946"]}],"id":[{"id":"10.13039\/501100008478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017700","name":"Fundaci\u00f3n Sales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The CSF-470 vaccine (VACCIMEL) plus BCG and GM-CSF as adjuvants has been assayed in cutaneous melanoma patients. In the adjuvant randomized Phase II study CASVAC-0401, vaccinated patients had longer distant metastasis-free survival (DMFS) than those treated with IFN\u03b12b. Five years after locking the data, an actualization was performed. The benefit in DMFS was maintained in the vaccinated group versus the IFN\u03b12b-treated group (<jats:italic>p<\/jats:italic> = 0.035), with a median DMFS of 96 months for VACCIMEL and 13 months for IFN\u03b12b. The favorable risk\u2013benefit ratio was maintained. DMFS was also analyzed as a single cohort in all the IIB, IIC, and III patients (<jats:italic>n<\/jats:italic> = 30) who had been treated with VACCIMEL. The median DMFS was 169 months, and at 48 months follow-up, it was 71.4%, which was not statistically different from DMFS of previously published results obtained in adjuvancy with ipilimumab, pembrolizumab, nivolumab, or dabrafenib\/trametinib. The possible toxicity of combining VACCIMEL with anti-immune checkpoint inhibitors (ICKi) was analyzed, especially since VACCIMEL was co-adjuvated with BCG in every vaccination. A patient with in-transit metastases was studied to produce a proof of concept. During treatment with VACCIMEL, the patient developed T-cell clones reactive towards tumor-associated antigens. Three years after ending the VACCIMEL study, the patient progressed and was treated with ICKi. During ICKi treatment, the patient did not reveal any toxicity due to previous BCG treatment. When she recurred after a 4-year treatment with nivolumab, a biopsy was obtained and immunohistochemistry and RNA-seq were performed. The tumor maintained expression of tumor-associated antigens and HLA-I and immune infiltration, with immunoreactive and immunosuppressive features. VACCIMEL plus BCG and GM-CSF is an effective treatment in adjuvancy for stages IIB, IIC, and III cutaneous melanoma patients, and it is compatible with subsequent treatments with ICKi.<\/jats:p>","DOI":"10.3389\/fimmu.2022.842555","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T11:08:17Z","timestamp":1648811297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases"],"prefix":"10.3389","volume":"13","author":[{"given":"Ana","family":"Mordoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Aris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibel","family":"Carri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia In\u00e9s","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Podaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos Trivi\u00f1o","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo Rub\u00e9n","family":"Cueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Marcela","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mordoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/NATURE12213","article-title":"Mutational Heterogeneity in Cancer and the Search for New Cancer-Associated Genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00103","article-title":"Melanoma Vaccines and Modulation of the Immune System in the Clinical Setting: Building From New Realities","volume":"3","author":"Madorsky-Rowdo","year":"2012","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/J.JID.2020.06.004","article-title":"The Genetic Basis of Vitiligo","volume":"141","author":"Spritz","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1611299","article-title":"Prolonged Survival in Stage III Melanoma With Ipilimumab Adjuvant Therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant Nivolumab Versus Ipilimumab in Resected Stage IIIB-C and Stage IV Melanoma (CheckMate 238): 4-Year Results From a Multicentre, Double-Blind, Randomised, Controlled, Phase 3 Trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant Pembrolizumab Versus Placebo in Resected Stage III Melanoma (EORTC 1325-MG\/KEYNOTE-054): Distant Metastasis-Free Survival Results From a Double-Blind, Randomised, Controlled, Phase 3 Trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/NATURE23003","article-title":"Personalized RNA Mutanome Vaccines Mobilize Poly-Specific Therapeutic Immunity Against Cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/S41571-020-00460-2","article-title":"Advances in the Development of Personalized Neoantigen-Based Therapeutic Cancer Vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000208258.79005.5f","article-title":"A Phase I Study of an Allogeneic Cell Vaccine (VACCIMEL) With GM-CSF in Melanoma Patients","volume":"29","author":"Barrio","year":"2006","journal-title":"J Immunother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00625","article-title":"Phase II Study of Adjuvant Immunotherapy With the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patie","volume":"8","author":"Mordoh","year":"2017","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.01147","article-title":"Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF","volume":"11","author":"Podaza","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00955","article-title":"Changes in the Tcr\u03b2 Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report","volume":"9","author":"Aris","year":"2018","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02213","article-title":"Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a Tcr\u03b2 Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood","volume":"10","author":"Aris","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.182.2.980","article-title":"PD-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic Vaccination","volume":"182","author":"Finnefrock","year":"2009","journal-title":"J Immunol"},{"key":"B15","unstructured":"Nct02362594"},{"key":"B16","unstructured":"Nct02388906"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40425-019-0771-1","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors (ICIs) in Cancer Patients With HIV, Hepatitis B, or Hepatitis C Viral Infection","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp698","article-title":"Fast and Accurate Long-Read Alignment With Burrows\u2013Wheeler Transform","volume":"26","author":"Li","year":"2010","journal-title":"Bioinformatics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/GB-2013-14-4-R36","article-title":"TopHat2: Accurate Alignment of Transcriptomes in the Presence of Insertions, Deletions and Gene Fusions","volume":"14","author":"Kim","year":"2013","journal-title":"Genome Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/BIOINFORMATICS\/BTP373","article-title":"VarScan: Variant Detection in Massively Parallel Sequencing of Individual and Pooled Samples","volume":"25","author":"Koboldt","year":"2009","journal-title":"Bioinformatics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/NBT.1621","article-title":"Transcript Assembly and Quantification by RNA-Seq Reveals Unannotated Transcripts and Isoform Switching During Cell Differentiation","volume":"28","author":"Trapnell","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2013a Python Framework to Work With High-Throughput Sequencing Data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13059-014-0550-8","article-title":"Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With Deseq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12885-019-6414-6","article-title":"A Systematic Analysis of Immune Genes and Overall Survival in Cancer Patients","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/S00262-017-1978-Y","article-title":"TANTIGEN: A Comprehensive Database of Tumor T Cell Antigens","volume":"66","author":"Olsen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02531","article-title":"Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants","volume":"9","author":"Pampena","year":"2018","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant Ipilimumab Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (EORTC 18071): A Randomised, Double-Blind, Phase 3 Trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2005493","article-title":"Five-Year Analysis of Adjuvant Dabrafenib Plus Trametinib in Stage III Melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced Secondary Analysis of Survival Data: Reconstructing the Data From Published Kaplan-Meier Survival Curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/JRSM.1362","article-title":"Estimating Hazard Ratios From Published Kaplan-Meier Survival Curves: A Methods Validation Study","volume":"10","author":"Saluja","year":"2019","journal-title":"Res Synth Methods"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1245\/S10434-018-6513-7","article-title":"Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/SCIIMMUNOL.ABF3861","article-title":"PD-1 Blockade Exacerbates Mycobacterium Tuberculosis Infection in Rhesus Macaques","volume":"6","author":"Kauffman","year":"2021","journal-title":"Sci Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/SCITRANSLMED.AAT2702","article-title":"Tuberculosis Following PD-1 Blockade for Cancer Immunotherapy","volume":"11","author":"Barber","year":"2019","journal-title":"Sci Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/INTIMM\/DXQ446","article-title":"PD-1-PD-L1 Pathway Impairs T(h)1 Immune Response in the Late Stage of Infection With Mycobacterium Bovis Bacillus Calmette-Gu\u00e9rin","volume":"22","author":"Sakai","year":"2010","journal-title":"Int Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1245\/S10434-007-9717-9","article-title":"Prognosis and Determinants of Outcome Following Locoregional or Distant Recurrence in Patients With Cutaneous Melanoma","volume":"15","author":"Francken","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCA.2021.08.044","article-title":"Adjuvant Treatment for Melanoma in Clinical Practice - Trial Versus Reality","volume":"158","author":"de Meza","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.842555\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T11:08:24Z","timestamp":1648811304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.842555\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2022.842555"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.842555","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"article-number":"842555"}}